Holen Sie sich die Stockscreener-App
71.20
0.62%
0.44
Handel nachbörslich:
71.20
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$70.76
Offen:
$70.87
24-Stunden-Volumen:
4.15M
Relative Volume:
0.94
Marktkapitalisierung:
$41.71B
Einnahmen:
$5.72B
Nettoeinkommen (Verlust:
$4.17B
KGV:
10.22
EPS:
6.97
Netto-Cashflow:
$259.90M
1W Leistung:
+1.86%
1M Leistung:
+2.76%
6M Leistung:
+4.25%
1J Leistung:
-20.93%
1-Tages-Spanne:
$70.52
$71.91
1-Wochen-Bereich:
$66.77
$71.91
52-Wochen-Spanne:
$58.93
$95.25
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Vergleichen Sie EW mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
71.20 | 41.71B | 5.72B | 4.17B | 259.90M | 6.97 |
|
ABT
Abbott Laboratories
|
129.70 | 224.94B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.25 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.67 | 132.32B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.70 | 106.07B | 33.20B | 4.26B | 5.47B | 3.29 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-30 | Hochstufung | Stifel | Hold → Buy |
| 2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | Truist | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
| 2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Herabstufung | Stifel | Buy → Hold |
| 2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Eingeleitet | Mizuho | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-27 | Bestätigt | Citigroup | Buy |
| 2022-01-27 | Bestätigt | Evercore ISI | Outperform |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Buy |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-30 | Bestätigt | Deutsche Bank | Hold |
| 2021-07-30 | Bestätigt | Jefferies | Buy |
| 2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
| 2021-07-30 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-30 | Bestätigt | Stifel | Buy |
| 2021-07-30 | Bestätigt | UBS | Neutral |
| 2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
| 2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-24 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025 - MarketScreener
Q1 2025 Earnings Alert: Edwards Lifesciences Unveils Critical Financial Report Date - Stock Titan
Edwards Lifesciences Insider Sold Shares Worth $663,196, According to a Recent SEC Filing - MarketScreener
Edwards Lifesciences CVP Donald Bobo Jr. sells $663k in stock - Investing.com India
Edwards Lifesciences CVP Donald Bobo Jr. sells $663k in stock By Investing.com - Investing.com South Africa
Edwards lands first CE mark for transfemoral mitral valve replacement - BioWorld MedTech
Edwards Lifesciences Gets CE Mark for Sapien M3 Mitral Valve System - MarketScreener
Edwards Lifesciences (EW) Secures CE Mark for Innovative Mitral Valve System | EW Stock News - GuruFocus
Edwards Sapien M3 Receives CE Mark, Becoming World'S First Transfemoral Transcatheter Mitral Valve Replacement System - MarketScreener
Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System - MarketScreener
Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System – Company AnnouncementFT.com - Financial Times
Investors in Edwards Lifesciences Corporation Should Contact Levi & Korsinsky Before December 13, 2024 to Discuss Your RightsEW - MarketScreener
Edwards Lifesciences Stock: A Deep Dive Into Analyst Perspectives (9 Ratings) - Benzinga
Truist Cuts Price Target on Edwards Lifesciences to $75 From $78, Keeps Hold Rating - MarketScreener
Edwards Lifesciences’ Quarterly Earnings Preview: What You Need to Know - Nasdaq
Edwards Lifesciences’ Quarterly Earnings Preview: What You Need To Know - Barchart.com
Edwards lifesciences CVP Daniel Lippis sells $21,183 in stock By Investing.com - Investing.com Canada
Edwards lifesciences CVP Daniel Lippis sells $21,183 in stock - Investing.com
CMS rolls out draft coverage memo for TEER for the tricuspid valve - BioWorld MedTech
Citigroup Adjusts Edwards Lifesciences Price Target to $84 From $83, Maintains Buy Rating - MarketScreener
Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry - Benzinga
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Medical Device Industry: Swept Up in the Tariffs, Diabetes Device Makers Bear the Brunt - Morningstar
Edwards Lifesciences (NYSE:EW) Presents Promising AS Treatment Data At ACC Session - Yahoo Finance
Edwards’ Early TAVR refutes surveillance recs for aortic stenosis - BioWorld MedTech
Sands Capital Select Growth Fund Sold Edwards Lifesciences Corporation (EW) For Better Opportunities - Yahoo Home
Jim Cramer Calls Edwards Lifesciences (EW) a Hold – Prefers Boston Scientific Right Now! - Insider Monkey
Edwards shares data supporting timely TAVR intervention - MassDevice
Huntington Beach man meets heart valve engineers who saved his life - Los Angeles Times
Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $85 From $92, Keeps Buy Rating - MarketScreener
Goldman Sachs Adjusts Price Target to Edwards Lifesciences to $85 From $92, Keeps Buy Rating - MarketScreener
Edwards Lifesciences CFO Scott Ullem sells $797,267 in stock - Investing.com
Edwards Lifesciences CFO Scott Ullem sells $797,267 in stock By Investing.com - Investing.com South Africa
Edwards Lifesciences: Double-Digit Top Line And EPS Growth Ahead - Seeking Alpha
S&P 500 Gains and Losses Today: Edwards Lifesciences Sinks on Outlook for Key Product - MSN
How Is The Market Feeling About Edwards Lifesciences? - Benzinga
Is Edwards Lifesciences Stock Underperforming the Nasdaq? - Nasdaq
Is Edwards Lifesciences Stock Underperforming The Nasdaq? - Barchart
Edwards Lifesciences downgraded at JPM, Truist on slower transcatheter valve growth - MSN
Edwards Lifesciences VP Donald Bobo Jr. sells $645,623 in stock By Investing.com - Investing.com Australia
Edwards Lifesciences VP Donald Bobo Jr. sells $645,623 in stock - Investing.com
Edwards Lifesciences CVP Daniel Lippis sells $27,792 in stock By Investing.com - Investing.com Australia
Edwards Lifesciences CEO Bernard Zovighian sells $428k in stock - Investing.com India
Edwards Lifesciences CVP Daniel Lippis sells $27,792 in stock - Investing.com India
Edwards Lifesciences CEO Bernard Zovighian sells $428k in stock By Investing.com - Investing.com UK
Edwards Lifesciences Corporation (EW): Among the Top Stocks to Buy According to Citadel Investment Group - Insider Monkey
Director Heisz Stone Sells Shares of Edwards Lifesciences Corp - GuruFocus.com
Edwards Lifesciences Corp. to Host Earnings Call - ACCESS Newswire
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):